Improve Quality & Yield For Viral Vector Manufacturing Using Osmolality: Unveiling Exciting New Data From Cell Gene Therapy Catapult

While cell and gene therapies can potentially revolutionize disease treatment, challenges remain in order to make these novel drugs accessible to larger patient populations. For now, downstream recoveries are as low as 5-30% for viral vector production, depending on the process. Manufacturing capacity, production yields, and supply chain logistics continue to be an area of focus for improvements. The key to improvement and success is through implementing high quality process design and process parameters to ensure robustness and reproducibility. An important question for scientists in the area is, ”What tools and checks can be implemented to ensure consistent product and process control”? Osmolality, a measure of solute concentration, has long been considered a critical measurement in Biopharma describing how much of a solute is present in a given solution. More recently, it has been shown to be strongly implicated across the entire gene therapy process workflow.